Cargando…

Belimumab versus anifrolumab in adults with systemic lupus erythematosus: an indirect comparison of clinical response at 52 weeks

OBJECTIVE: To generate comparative efficacy evidence of belimumab versus anifrolumab in SLE that can inform treatment practices. METHODS: The SLE Responder Index (SRI)-4 response at 52 weeks of belimumab versus anifrolumab was evaluated with an indirect treatment comparison. The evidence base consis...

Descripción completa

Detalles Bibliográficos
Autores principales:	Neupane, Binod, Shukla, Pragya, Slim, Mahmoud, Martin, Amber, Petri, Michelle, Bertsias, George K, Kim, Alfred H J, Fanouriakis, Antonis, Levy, Roger A, Chauhan, Deven, Ballew, Nick
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BMJ Publishing Group 2023
Materias:	Immunology and Inflammation
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10186457/ https://www.ncbi.nlm.nih.gov/pubmed/37147022 http://dx.doi.org/10.1136/lupus-2023-000907

Ejemplares similares

Letter to the Editor: indirect treatment comparison of anifrolumab efficacy versus belimumab in adults with systemic lupus erythematosus
por: Ballew, Nick, et al.
Publicado: (2022)

Letter in reply: indirect treatment comparison of anifrolumab efficacy versus belimumab in adults with systemic lupus erythematosus
por: Bruce, Ian N, et al.
Publicado: (2022)

Belimumab or anifrolumab for systemic lupus erythematosus? A risk-benefit assessment
por: Kirou, Kyriakos A., et al.
Publicado: (2022)

High-dimensional analysis of T-cell profiling variations following belimumab treatment in systemic lupus erythematosus
por: Maeda, Shinji, et al.
Publicado: (2023)

Changing paradigms in the treatment of systemic lupus erythematosus
por: Fanouriakis, Antonis, et al.
Publicado: (2019)

Anifrolumab for systemic lupus erythematosus
Publicado: (2022)

Clinical response trajectories and drug persistence in systemic lupus erythematosus patients on belimumab treatment: A real-life, multicentre observational study
por: Nikoloudaki, Myrto, et al.
Publicado: (2023)

Editorial: Lupus and the Brain: Advances in Neuropsychiatric Systemic Lupus Erythematosus
por: Fanouriakis, Antonis, et al.
Publicado: (2019)

Anifrolumab for Adolescent Discoid Lupus Erythematosus
por: Shaw, Katharina S., et al.
Publicado: (2023)

Efficacy of belimumab in two serologically distinct high disease activity subgroups of patients with systemic lupus erythematosus: post-hoc analysis of data from the phase III programme
por: Maslen, Toni, et al.
Publicado: (2021)

Impact of Belimumab on Organ Damage in Systemic Lupus Erythematosus
por: Urowitz, Murray B., et al.
Publicado: (2022)

Reductions in circulating B cell subsets and immunoglobulin G levels with long-term belimumab treatment in patients with SLE
por: Struemper, Herbert, et al.
Publicado: (2022)

Belimumab in systemic lupus erythematosus
por: Vilas-Boas, Andreia, et al.
Publicado: (2015)

Belimumab in Systemic Lupus Erythematosus
por: Srivastava, Ankita
Publicado: (2016)

Belimumab for systemic lupus erythematosus – Focus on lupus nephritis
por: Plüß, Marlene, et al.
Publicado: (2022)

Relationship of anifrolumab pharmacokinetics with efficacy and safety in patients with systemic lupus erythematosus
por: Chia, Yen Lin, et al.
Publicado: (2021)

Nonlinear Population Pharmacokinetics of Anifrolumab in Healthy Volunteers and Patients With Systemic Lupus Erythematosus
por: Almquist, Joachim, et al.
Publicado: (2022)

Pharmacokinetics of Belimumab in Children With Systemic Lupus Erythematosus
por: Dimelow, Richard, et al.
Publicado: (2020)

Belimumab in the treatment of systemic lupus erythematosus: high disease activity predictors of response
por: van Vollenhoven, Ronald F, et al.
Publicado: (2012)

Impact of systemic lupus erythematosus disease activity, hydroxychloroquine and NSAID on the risk of subsequent organ system damage and death: analysis in a single US medical centre
por: Hill, Deanna D, et al.
Publicado: (2021)

Evaluation of anifrolumab safety in systemic lupus erythematosus: A meta-analysis and systematic review
por: Liu, Zhihui, et al.
Publicado: (2022)

Management of Pediatric Systemic Lupus Erythematosus: Focus on Belimumab
por: Guzman, Marla, et al.
Publicado: (2020)

Advances in Systemic Lupus Erythematosus (SLE): A case for optimism
por: Fanouriakis, Antonis, et al.
Publicado: (2017)

Spotlight on anifrolumab and its potential for the treatment of moderate-to-severe systemic lupus erythematosus: evidence to date
por: Felten, Renaud, et al.
Publicado: (2019)

Anifrolumab, an Anti–Interferon‐α Receptor Monoclonal Antibody, in Moderate‐to‐Severe Systemic Lupus Erythematosus
por: Furie, Richard, et al.
Publicado: (2017)

Relationship Between Anifrolumab Pharmacokinetics, Pharmacodynamics, and Efficacy in Patients With Moderate to Severe Systemic Lupus Erythematosus
por: Chia, Yen Lin, et al.
Publicado: (2022)

Role of Anifrolumab in Refractory Cutaneous Manifestations of Lupus Erythematosus: A Case Series and Literature Review
por: Khan, Muhammad Atif, et al.
Publicado: (2023)

Viewpoint on anifrolumab in patients with systemic lupus erythematosus and a high unmet need in clinical practice
por: Tanaka, Yoshiya
Publicado: (2023)

Belatacept in kidney transplant patients with systemic lupus erythematosus
por: Carrión-Barberà, Irene, et al.
Publicado: (2019)

Intermuscular adipose tissue in patients with systemic lupus erythematosus
por: Gamboa, Jorge Luis, et al.
Publicado: (2022)

Molecular Taxonomy of Systemic Lupus Erythematosus Through Data-Driven Patient Stratification: Molecular Endotypes and Cluster-Tailored Drugs
por: Garantziotis, Panagiotis, et al.
Publicado: (2022)

Belimumab: First targeted biological treatment for systemic lupus erythematosus
por: Dubey, Ashok K., et al.
Publicado: (2011)

Cerebrovascular Events in Systemic Lupus Erythematosus: Diagnosis and Management
por: Nikolopoulos, Dionysis, et al.
Publicado: (2019)

Belimumab use during pregnancy: Interim results of the belimumab pregnancy registry
por: Juliao, Patricia, et al.
Publicado: (2022)

Systemic Lupus Erythematosus and COVID-19
por: Pappa, Maria, et al.
Publicado: (2023)

Long-term anifrolumab safe in SLE
por: McHugh, Jessica
Publicado: (2023)

Clinical Pharmacokinetics, Pharmacodynamics, and Immunogenicity of Anifrolumab
por: Tang, Weifeng, et al.
Publicado: (2023)

Restoration of aberrant gene expression of monocytes in systemic lupus erythematosus via a combined transcriptome-reversal and network-based drug repurposing strategy
por: Nikolakis, Dimitrios, et al.
Publicado: (2023)

Birth Registry of Women With Systematic Lupus Erythematosus: The Greek Experience
por: Ntali, Stella, et al.
Publicado: (2018)

Validity of the Italian algorithm for the attribution of neuropsychiatric events in systemic lupus erythematosus: a retrospective multicentre international diagnostic cohort study
por: Bortoluzzi, Alessandra, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_t63sdr36cocmgbvnnflf0chjpp